Skip to main content
. 2015 May 14;48(1):71–79. doi: 10.4143/crt.2015.018

Fig. 1.

Fig. 1.

Association between genotype and survival outcome. In early stage of esophageal cancer, FGFR4 Gly388 allele (G/G) patients show better trends of progression-free survival (A) and overall survival (C) than FGFR4 Arg388 carriers (G/A or A/A) without statistical significance. However, the progression-free survival (B) and overall survival (D) in advanced stage of esophageal cancer patients show comparable outcomes regardless of genotypes.